Biopharmaceutical cold chain logistics market seen reaching $25.87B by 2030

By AI, Created 4:32 PM UTC, May 18, 2026, /AGP/ – The biopharmaceutical cold chain logistics market is projected to rise from $16.47 billion in 2025 to $18 billion in 2026, driven by vaccine distribution, clinical trials and tighter temperature-control needs. The Business Research Company says personalized medicine and AI-enabled monitoring will help push the market to $25.87 billion by 2030.

Why it matters: - Biopharmaceutical cold chain logistics protects temperature-sensitive medicines and vaccines from manufacture to patient use. - Faster growth in personalized medicine is increasing the need for tightly controlled transport and storage. - The market’s expansion points to more spending on monitoring, refrigerated transport and specialized packaging across the life sciences supply chain.

What happened: - The Business Research Company released its “Biopharmaceutical Cold Chain Logistics Market Report 2026” on May 14, 2026. - The report says the market will grow from $16.47 billion in 2025 to $18 billion in 2026. - The report forecasts the market will reach $25.87 billion by 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period.

The details: - The 2025-to-2026 growth forecast implies a 9.3% CAGR. - The 2026-to-2030 outlook implies a 9.5% CAGR. - Growth drivers include higher biopharmaceutical manufacturing output, more vaccine distribution, expanded clinical trial logistics, broader refrigerated transportation networks and wider use of passive insulated packaging. - The report points to greater use of active temperature-controlled containers, cold chain monitoring services, reusable thermal packaging, short-term transit storage and AI and IoT integration in logistics systems. - Key trends include temperature-controlled packaging, last-mile cold chain deliveries, real-time tracking, more refrigerated and cryogenic storage capacity and stricter compliance with regulatory standards. - The report defines biopharmaceutical cold chain logistics as the transportation and storage of delicate biopharmaceutical products under precisely regulated temperature conditions. - The report says that process is essential to preserve safety, stability and therapeutic effectiveness from factory to end user. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The release includes a free sample report link: Download the free sample. - The release also links to the full report: View the full report.

Between the lines: - Personalized medicine is a major demand driver because it depends on therapies that often must remain within strict temperature ranges. - The report cites the Personalized Medicine Coalition as saying the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - Among those approvals were seven cancer drugs and three treatments for other medical conditions. - The growth outlook suggests logistics providers will need more infrastructure and better visibility tools, not just more trucking and warehousing capacity.

What’s next: - The market is expected to keep expanding as active containers, tracking services and reusable packaging gain wider adoption. - AI and IoT use in logistics systems is expected to deepen as operators try to improve temperature control and shipment visibility. - Regional growth may shift more investment toward Asia-Pacific as demand rises there faster than in other markets.

The bottom line: - Temperature control is becoming a bigger competitive and operational requirement in biopharma logistics, and the market is on track for steady double-digit-style growth through 2030.